Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data

Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: Preclinical and clinical aspects

(2015) Omar Abdel-Rahman   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study

(2014) Emilio Bajetta et al.   CANCER

RAF signaling in neuroendocrine neoplasms: From bench to bedside

(2014) Nicola Fazio et al.   CANCER TREATMENT REVIEWS

Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours

(2014) V. Ramundo et al.   CLINICAL ENDOCRINOLOGY

Risk of mucocutaneous toxicities in patients with solid tumors treated with everolimus; a systematic review and meta-analysis

(2014) Omar Abdel-Rahman et al.   Expert Review of Anticancer Therapy

Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature

(2014) Omar Abdel-Rahman et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Metronomics: towards personalized chemotherapy?

(2014) Nicolas André et al.   Nature Reviews Clinical Oncology

Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations

(2014) Omar Abdel-Rahman   TUMOR BIOLOGY

Biotherapies for GEP-NETs

(2013) Kjell Öberg   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes

(2013) D J Pinato et al.   BRITISH JOURNAL OF CANCER

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

(2013) Jennifer A. Chan et al.   CANCER

Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors

(2013) Jennifer A. Chan et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours

(2013) Juan W. Valle et al.   CANCER TREATMENT REVIEWS

Targeted therapy with kinase inhibitors in aggressive endocrine tumors

(2013) Vincenzo Marotta et al.   EXPERT OPINION ON PHARMACOTHERAPY

Gastroenteropancreatic Neuroendocrine Tumors: Update on Therapeutics

(2012) Alex Ganetsky et al.   ANNALS OF PHARMACOTHERAPY

Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in advanced neuroendocrine tumors

(2012) Jennifer A Chan et al.   ENDOCRINE-RELATED CANCER

TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study

(2012) G. Rindi et al.   JNCI-Journal of the National Cancer Institute

A unifying model for mTORC1-mediated regulation of mRNA translation

(2012) Carson C. Thoreen et al.   NATURE

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs

(2012) Isabel Fernandes et al.   OncoTargets and Therapy

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Angiogenic markers endoglin and vascular endothelial growth factor in gastroenteropancreatic neuroendocrine tumors

(2011) Patricia Kuiper   WORLD JOURNAL OF GASTROENTEROLOGY

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Compensatory activation of Akt in response to mTOR and Raf inhibitors – A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

(2010) Kathrin Zitzmann et al.   CANCER LETTERS

VEGF Secretion by Neuroendocrine Tumor Cells Is Inhibited by Octreotide and by Inhibitors of the PI3K/AKT/mTOR Pathway

(2010) Karine Villaume et al.   NEUROENDOCRINOLOGY

Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors

(2009) Takashi Shida et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

(2009) Dik J Kwekkeboom et al.   ENDOCRINE-RELATED CANCER

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

(2009) Anja Rinke et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors

(2008) Ulrich‐Frank Pape et al.   CANCER

Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Angiogenesis and Tumor Progression in Neuroendocrine Digestive Tumors

(2008) Gilles Poncet et al.   JOURNAL OF SURGICAL RESEARCH

Gastroenteropancreatic neuroendocrine tumours

(2008) Irvin M Modlin et al.   LANCET ONCOLOGY

Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line

(2007) Simona Grozinsky-Glasberg et al.   NEUROENDOCRINOLOGY